- Joined
- Nov 2, 2006
- Messages
- 1,047
http://www.medscape.com/viewarticle/703878?src=rss
June 4, 2009 (Chicago, Illinois) — One-year data from the Study of Immunomodulator Naive Patients in Crohn's Disease (SONIC) show that nearly three quarters of patients with Crohn's disease who failed to respond to initial treatment with conventional therapies respond to combination therapy with infliximab (Remicade, Centocor Ortho Biotech Inc) and azathioprine.
Response rates were significantly lower with monotherapy.
June 4, 2009 (Chicago, Illinois) — One-year data from the Study of Immunomodulator Naive Patients in Crohn's Disease (SONIC) show that nearly three quarters of patients with Crohn's disease who failed to respond to initial treatment with conventional therapies respond to combination therapy with infliximab (Remicade, Centocor Ortho Biotech Inc) and azathioprine.
Response rates were significantly lower with monotherapy.
